|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
17
|
|
pubmed:dateCreated |
2004-9-9
|
|
pubmed:abstractText |
To develop a potentially superior adjuvant chemotherapy regimen, we conducted a pilot study of dose-dense 5-fluorouracil, epirubicin, and cyclophosphamide (FEC) followed by weekly alternating taxanes. The primary objective was to determine the feasibility of the regimen; the secondary objective was to estimate the disease-free and overall survival.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Sep
|
|
pubmed:issn |
1078-0432
|
|
pubmed:author |
pubmed-author:CurrieViolante EVE,
pubmed-author:D'AndreaGabriella MGM,
pubmed-author:DangChau TCT,
pubmed-author:DicklerMaura NMN,
pubmed-author:FornierMonicaM,
pubmed-author:HudisClifford ACA,
pubmed-author:HurriaArtiA,
pubmed-author:LakeDianaD,
pubmed-author:MoynahanMary EME,
pubmed-author:NortonLarryL,
pubmed-author:PanageasKatherine SKS,
pubmed-author:RobsonMark EME,
pubmed-author:SeidmanAndrew DAD,
pubmed-author:TheodoulouMariaM
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
1
|
|
pubmed:volume |
10
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
5754-61
|
|
pubmed:dateRevised |
2006-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:15355903-Adult,
pubmed-meshheading:15355903-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:15355903-Breast Neoplasms,
pubmed-meshheading:15355903-Cyclophosphamide,
pubmed-meshheading:15355903-Disease-Free Survival,
pubmed-meshheading:15355903-Dose-Response Relationship, Drug,
pubmed-meshheading:15355903-Epirubicin,
pubmed-meshheading:15355903-Feasibility Studies,
pubmed-meshheading:15355903-Female,
pubmed-meshheading:15355903-Fluorouracil,
pubmed-meshheading:15355903-Granulocyte Colony-Stimulating Factor,
pubmed-meshheading:15355903-Humans,
pubmed-meshheading:15355903-Lymph Nodes,
pubmed-meshheading:15355903-Middle Aged,
pubmed-meshheading:15355903-Paclitaxel,
pubmed-meshheading:15355903-Pilot Projects,
pubmed-meshheading:15355903-Risk Factors,
pubmed-meshheading:15355903-Survival Rate,
pubmed-meshheading:15355903-Taxoids
|
|
pubmed:year |
2004
|
|
pubmed:articleTitle |
Phase II study of feasibility of dose-dense FEC followed by alternating weekly taxanes in high-risk, four or more node-positive breast cancer.
|
|
pubmed:affiliation |
Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, New York, USA. dangc@mskcc.org
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Research Support, Non-U.S. Gov't,
Clinical Trial, Phase II
|
